Intratumoral chemotherapy for lung cancer: Re-challenge current targeted therapies

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 571-583

  Hohenforst Schmidt, Wolfgang ^a   Zarogoulidis, Paul ^b,c   Darwiche, Kaid ^c   Vogl, Thomas ^d   Goldberg, Eugene P ^e   Huang, Haidong ^f   Simoff, Michael ^g   Li, Qiang ^f   Browning, Robert ^h   Turner, Francis J ⁱ   Le Pivert, Patrick ^j   Spyratos, Dionysios ^b   Zarogoulidis, Konstantinos ^b   Celikoglu, Seyhan I ^k   Celikoglu, Firuz ^k   Brachmann, Johannes ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c RUHRLANDKLINIK   (Germany)

^d GOETHE UNIVERSITY   (Germany)

^e University of Florida   (United States)

^f SECOND MILITARY MEDICAL UNIVERSITY   (China)

^g WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h WALTER REED ARMY MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^j Interventional Drug Delivery Systems and Strategies (ID2S2)   (United States)

^k ISTANBUL UNIVERSITY   (Turkey)

more..

Author keywords

Chemotherapy; Cisplatin; Intratumoral; Lung cancer; Lymph nodes

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; GEMCITABINE; MITOMYCIN; VINCRISTINE;

ARTICLE; BLOOD TOXICITY; BONE METASTASIS; CANCER PROGNOSIS; CANCER STAGING; CLINICAL PROTOCOL; DRUG EFFICACY; DRUG FORMULATION; DRUG INFUSION; DRUG SAFETY; ENDOBRONCHIAL ULTRASONOGRAPHY; HUMAN; KARNOFSKY PERFORMANCE STATUS; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; QUALITY OF LIFE; REGIONAL PERFUSION; TREATMENT RESPONSE; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; MORTALITY; NEEDLE BIOPSY; PATHOLOGY;

ANTINEOPLASTIC AGENTS; BIOPSY, NEEDLE; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING;

EID: 84880436777     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S46393     Document Type: Article

References (92)

1. Hinoda Y. [Molecular targeted cancer therapy and genetic tests-chairman's introductory remarks.] Rinsho Byori. 2012;60(10):967-968. Japanese.
2. Domvri K, Darwiche K, Zarogoulidis P, Zarogoulidis K. Following the crumbs: from tissue samples, to pharmacogenomics, to NSCLC therapy. Transl Lung Cancer Res. 2012. DOI: 10.3978/j.issn.2218-6751.2012.12.06.
3. Saijo N. The role of pharmacoethnicity in the development of cytotoxic and molecular targeted drugs in oncology. Yonsei Med J. 2013;54(1):1-14.
4. Savonarola A, Palmirotta R, Guadagni F, Silvestris F. Pharmacogenet-ics and pharmacogenomics: role of mutational analysis in anti-cancer targeted therapy. Pharmacogenomics J. 2012;12(4):277-286.
5. Mamot C, Drummond DC, Noble CO, et al. Epidermal growth factor receptor-targeted immunoliposomes signifcantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res. 2005;65(24): 11631-11638.
6. Giovannetti E, Toffalorio F, De Pas T, Peters GJ. Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape? Pharmacogenomics. 2012;13(9):1073-1086.
7. Yin JY, Huang Q, Zhao YC, Zhou HH, Liu ZQ. Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients. PLoS One. 2012;7(6):e38150.
8. Mayo C, Bertran-Alamillo J, Molina-Vila MA, Gimenez-Capitan A, Costa C, Rosell R. Pharmacogenetics of EGFR in lung cancer: perspectives and clinical applications. Pharmacogenomics. 2012;13(7):789-802.
9. Wang S, Peng L, Li J, et al. A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as frst-line therapy for eastern asian nonsquamous non-small-cell lung cancer. PLoS One. 2013;8(3):e55917.
10. Ihbe-Heffnger A, Paessens B, Berger K, et al. The impact of chemotherapy-induced side effects on medical care usage and cost in German hospital care-an observational analysis on non-small-cell lung cancer patients. Support Care Cancer. 2013;21(6):1665-1675.
11. Mylonaki E, Manika K, Zarogoulidis P, et al. In vivo synergistic cyto-genetic effects of aminophylline on lymphocyte cultures from patients with lung cancer undergoing chemotherapy. Mutat Res. 2012;740(1-2): 1-5.
12. Boutsikou E, Kontakiotis T, Zarogoulidis P, et al. Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer. Onco Targets Ther. 2013;6:125-134.
13. Zarogoulidis K, Eleftheriadou E, Kontakiotis T, et al. Long acting somatostatin analogues in combination to antineoplastic agents in the treatment of small cell lung cancer patients. Lung Cancer. 2012;76(1): 84-88.
14. Zarogoulidis K, Ziogas E, Papagiannis A, et al. Interferon alpha-2a and combined chemotherapy as frst line treatment in SCLC patients: a randomized trial. Lung Cancer. 1996;15(2):197-205.
15. Hohenforst-Schmidt W. Intratumoral Chemotherapy (ITC)-a forgotten option at least in functionally or oncologically driven palliation! Paper presented at: 16th WCBE 20102010.
16. Celikoglu F, Celikoglu SI, Goldberg EP. Bronchoscopic intratumoral chemotherapy of lung cancer. Lung Cancer. 2008;61(1):1-12.
17. Kar UK, Srivastava MK, Andersson A, et al. Novel CCL21-vault nanocapsule intratumoral delivery inhibits lung cancer growth. PLoS One. 2011;6(5):e18758.
18. Macha HN, Freitag L. The role of brachytherapy in the treatment and control of central bronchial carcinoma. Monaldi Arch Chest Dis. 1996;51(4):325-328.
19. Freitag L, Ernst A, Thomas M, Prenzel R, Wahlers B, Macha HN. Sequential photodynamic therapy (PDT) and high dose brachytherapy for endobronchial tumour control in patients with limited bronchogenic carcinoma. Thorax. 2004;59(9):790-793.
20. Porpodis K, Karanikas M, Zarogoulidis P, et al. A case of typical pulmonary carcinoid tumor treated with bronchoscopic therapy followed by lobectomy. J Multidiscip Healthc. 2012;5:47-51.
21. Freitag L, Macha H-N, Loddenkemper R. Interventional bronchoscopic procedures. Eur Resp mon. 2001;17:272-304.
22. Zarogoulidis P, Chatzaki E, Porpodis K, et al. Inhaled chemotherapy in lung cancer: future concept of nanomedicine. Int J Nanomedicine. 2012;7:1551-1572.
23. Zarogoulidis P, Eleftheriadou E, Sapardanis I, et al. Feasibility and effectiveness of inhaled carboplatin in NSCLC patients. Invest New Drugs. 2012;30(4):1628-1640.
24. Darwiche K, Zarogoulidis P, Karamanos NK, et al. Efficacy versus safety concerns for aerosol chemotherapy in non-small-cell lung cancer: a future dilemma for micro-oncology. Future Oncol. 2013;9(4): 505-525.
25. Fujiwara T, Tanaka N, Kanazawa S, et al. Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2006;24(11): 1689-1699.
26. Zarogoulidis P, Chatzaki E, Hohenforst-Schmidt W, et al. Management of malignant pleural effusion by suicide gene therapy in advanced stage lung cancer: a case series and literature review. Cancer Gene Ther. 2012;19(9):593-600.
27. Jia Y, Yuan M, Yuan H, et al. Co-encapsulation of magnetic Fe3O4 nano-particles and doxorubicin into biodegradable PLGA nanocarriers for intratumoral drug delivery. Int J Nanomedicine. 2012;7:1697-1708.
28. Cunha-Filho MS, Alvarez-Lorenzo C, Martinez-Pacheco R, Landin M. Temperature-sensitive gels for intratumoral delivery of beta- lapachone: effect of cyclodextrins and ethanol. ScientifcWorldJournal. 2012;2012: 126723.
29. Ahmed M, Moussa M, Goldberg SN. Synergy in cancer treatment between liposomal chemotherapeutics and thermal ablation. Chem Phys Lipids. 2012;165(4):424-437.
30. Horev-Drori G, Cooks T, Bittan H, et al. Local control of experimental malignant pancreatic tumors by treatment with a combination of chemotherapy and intratumoral 224 radium-loaded wires releasing alpha-emitting atoms. Transl Res. 2012;159(1):32-41.
31. Ginsberg RJ. Resection of non-small cell lung cancer: how much and by what route. Chest. 1997;112(Suppl 4):203S-205S.
32. McGinn CJ, Shewach DS, Lawrence TS. Radiosensitizing nucleosides. J Natl Cancer Inst. 1996;88(17):1193-1203.
33. Pauwels B, Korst AE, Lardon F, Vermorken JB. Combined modality therapy of gemcitabine and radiation. Oncologist. 2005;10(1):34-51.
34. Shewach DS, Lawrence TS. Antimetabolite radiosensitizers. J Clin Oncol. 2007;25(26):4043-4050.
35. Arazi L, Cooks T, Schmidt M, Keisari Y, Kelson I. Treatment of solid tumors by interstitial release of recoiling short-lived alpha emitters. Phys Med Biol. 2007;52(16):5025-5042.
36. Celikoglu F, Celikoglu SI. Intratumoural chemotherapy with 5- fuorouracil for palliation of bronchial cancer in patients with severe airway obstruction. J Pharm Pharmacol. 2003;55(10):1441-1448.
37. Hohenforst-Schmidt W. Intratumoral chemotherapy (ITC) as adjunct therapy in NSCLC iiia-iv prolongs life. Poster presented at: International Conference and Exhibition on Cancer Science and Therapy; August 15-17, 2011; Las Vegas, N V.
38. Bae YH. Interview with Dr Yo u Han Bae: ligand-mediated versus 'passive' targeting approaches in nanoparticle oncology research. Ther Deliv. 2012;3(8):933-936.
39. Yang W, Ahmed M, Elian M, et al. Do liposomal apoptotic enhancers increase tumor coagulation and end-point survival in percutaneous radiofrequency ablation of tumors in a rat tumor model? Radiology. 2010;257(3):685-696.
40. Le Pivert PJ, Morrison DR, Haddad RS, et al. Percutaneous tumor ablation: microencapsulated echo-guided interstitial chemotherapy combined with cryosurgery increases necrosis in prostate cancer. Technol Cancer Res Treat. 2009;8(3):207-216.
41. Lin X, Gao R, Zhang Y, et al. Lipid nanoparticles for chemotherapeutic applications: strategies to improve anticancer effcacy. Expert Opin Drug Deliv. 2012;9(7):767-781.
42. Xie H, Goins B, Bao A, Wang ZJ, Phillips WT. Effect of intratumoral administration on biodistribution of 64Cu-labeled nanoshells. Int J Nanomedicine. 2012;7:2227-2238.
43. Sim H, Bibee K, Wickline S, Sept D. Pharmacokinetic modeling of tumor bioluminescence implicates effux, and not infux, as the bigger hurdle in cancer drug therapy. Cancer Res. 2011;71(3):686-692.
44. Zhao W, Zhuang S, Qi XR. Comparative study of the in vitro and in vivo characteristics of cationic and neutral liposomes. Int J Nanomedicine. 2011;6:3087-3098.
45. Fang J, Qin H, Nakamura H, Tsukigawa K, Shin T, Maeda H. Carbon monoxide, generated by heme oxygenase-1, mediates the enhanced permeability and retention effect in solid tumors. Cancer Sci. 2012;103(3): 535-541.
46. Celikoglu F, Celikoglu SI, York AM, Goldberg EP. Intratumoral administration of cisplatin through a bronchoscope followed by irradiation for treatment of inoperable non-small cell obstructive lung cancer. Lung Cancer. 2006;51(2):225-236.
47. Celikoglu F, Celikoglu SI, Goldberg EP. Intratumoural chemotherapy of lung cancer for diagnosis and treatment of draining lymph node metastasis. J Pharm Pharmacol. 2010;62(3):287-295.
48. Celikoglu SI, Karayel T, Demirci S, Celikoglu F, Cagatay T. Direct injection of anti-cancer drugs into endobronchial tumours for palliation of major airway obstruction. Postgrad Med J. 1997;73(857):159-162.
49. Horng G, Askari S, Choi Y, Grundfest W. Sustained Localized Drug Delivery In Mammalian Lung By Bronchoscopy. Paper presented at: American Thoracic Society 2012 International Conference; May 18-23, 2012; San Francisco, CA.
50. Ye h CT, Chen HC, Sung CM, et al. Retrospective comparison between a regular and a split-dose protocol of 5-fuorouracil, cisplatin, and mitox-antrone for the treatment of far advanced hepatocellular carcinoma. BMC Cancer. 2011;11:117.
51. Goldberg E P, Hadba AR, Almond BA, Marotta JS. Intratumoral cancer chemotherapy and immunotherapy: opportunities for nonsystemic pre-operative drug delivery. J Pharm Pharmacol. 2002;54(2):159-180.
52. Vogl TJ, Wissniowski TT, Naguib NN, et al. Activation of tumor-specific T lymphocytes after laser-induced thermotherapy in patients with colorectal liver metastases. Cancer Immunol Immunother. 2009;58(10):1557-1563.
53. Monga S P, Wadleigh R, Sharma A, et al. Intratumoral therapy of cispla-tin/epinephrine injectable gel for palliation in patients with obstructive esophageal cancer. Am J Clin Oncol. 2000;23(4):386-392.
54. Wagai F, Kinoshita M, Shiraki R, Watanabe H, Kitamura S. [The direct injection of several anti-cancer drugs into the primary lung cancer lesion through a fberoptic bronchoscope (author's transl).] Nihon Kyobu Shikkan Gakkai Zasshi. 1982;20(2):170-175. Japanese.
55. Liu M, Ma P, Lu Z. [Local chemotherapy by fbrobronchoscopy for advanced bronchogenic carcinoma.] Zhonghua Jie He He Hu Xi Za Zhi. 2000;23(9):550-551. Chinese.
56. Celikoglu SI, Celikoglu F, Goldberg EP. Endobronchial intratumoral chemotherapy (EITC) followed by surgery in early non-small cell lung cancer with polypoid growth causing erroneous impression of advanced disease. Lung Cancer. 2006;54(3):339-346.
57. Nader AD. Intratumoral chemotherapy as an adjuvant to endobronchial brachytherapy. Chest. 2007;132(Suppl):459.
58. Jabbardarjani H, Safara H, Kharabian S, Reza M. Endobronchial chemotherapy in malignant airway lesions of the lung: Report of 3 years experience. J Bronchology. 2007;14:242-245.
59. Ramos HC, Ruivo I, deBrito U. Use of intratumoral cisplatinium in lung cancer. Experimental Pathology and Healt Science. 2008;2(2): 45-46.
60. He J, Ying W, Yang H, et al. Gemcitabine plus cisplatin chemotherapy with concurrent para-toluenesulfonamide local injection therapy for peripherally advanced nonsmall cell lung cancer larger than 3 cm in the greatest dimension. Anticancer Drugs. 2009;20(9):838-844.
61. Brincker H. Direct intratumoral chemotherapy. Crit Rev Oncol Hematol. 1993;15(2):91-98.
62. Li C, Wang Y, Zhang X, Deng L, Zhang Y, Chen Z. Tumor-targeted liposomal drug delivery mediated by a diseleno bond-stabilized cyclic peptide. Int J Nanomedicine. 2013;8:1051-1062.
63. Kosacka M, Piesiak P, Kowal A, Golecki M, Jankowska R. Galectin-3 and cyclin D1 expression in non-small cell lung cancer. J Exp Clin Cancer Res. 2011;30:101.
64. Peiris PM, Bauer L, Toy R, et al. Enhanced delivery of chemotherapy to tumors using a multicomponent nanochain with radio-frequency-tunable drug release. ACS Nano. 2012;6(5):4157-4168.
65. Werner JA, Kehrl W, Pluzanska A, et al. A phase III placebo-controlled study in advanced head and neck cancer using intratumoural cisplatin/ epinephrine gel. Br J Cancer. 2002;87(9):938-944.
66. Callahan DJ, Liu W, Li X, et al. Triple stimulus-responsive polypeptide nanoparticles that enhance intratumoral spatial distribution. Nano Lett. 2012;12(4):2165-2170.
67. Govindarajan S, Sivakumar J, Garimidi P, et al. Targeting human epidermal growth factor receptor 2 by a cell-penetrating peptide-affbody bioconjugate. Biomaterials. 2012;33(8):2570-2582.
68. Gopal V, Guruprasad K. Structure prediction and validation of an affbody engineered for cell-specifc nucleic acid targeting. Syst Synth Biol. 2010;4(4):293-297.
69. Liu Q, Li R, Zhu Z, et al. Enhanced antitumor effcacy, biodistribution and penetration of docetaxel-loaded biodegradable nanoparticles. Int J Pharm. 2012;430(1-2):350-358.
70. Watson KD, Lai C Y, Qin S, et al. Ultrasound increases nanoparticle delivery by reducing intratumoral pressure and increasing transport in epithelial and epithelial-mesenchymal transition tumors. Cancer Res. 2012;72(6):1485-1493.
71. Hecht JR, Farrell JJ, Senzer N, et al. EUS or percutaneously guided intratumoral TNFerade biologic with 5-fuorouracil and radiotherapy for frst-line treatment of locally advanced pancreatic cancer: a phase I/II study. Gastrointest Endosc. 2012;75(2):332-338.
72. Hanna N, Ohana P, Konikoff FM, et al. Phase 1/2a, dose-escalation, safety, pharmacokinetic and preliminary effcacy study of intratumoral administration of BC-819 in patients with unresectable pancreatic cancer. Cancer Gene Ther. 2012;19(6):374-381.
73. Geletneky K, Huesing J, Rommelaere J, et al. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol. BMC Cancer. 2012;12:99.
74. Zheng X, Zhou F, Wu B, Chen WR, Xing D. Enhanced tumor treatment using biofunctional indocyanine green-containing nanostructure by intratumoral or intravenous injection. Mol Pharm. 2012;9(3): 514-522.
75. Luo X, Xie C, Wang H, Liu C, Yan S, Li X. Antitumor activities of emulsion electrospun fbers with core loading of hydroxycamp-tothecin via intratumoral implantation. Int J Pharm. 2012;425(1-2): 19-28.
76. Luo X, Xu G, Song H, et al. Promoted antitumor activities of acid-labile electrospun fbers loaded with hydroxycamptothecin via intratumoral implantation. Eur J Pharm Biopharm. 2012;82(3):545-553.
77. Tsuda K, Yamanaka K, Linan W, et al. Intratumoral injection of Pro-pionibacterium acnes suppresses malignant melanoma by enhancing Th1 immune responses. PLoS One. 2011;6(12):e29020.
78. Oh SM, Oh K, Lee DS. Intratumoral administration of secondary lymphoid chemokine and unmethylated cytosine-phosphorothioate-guanine oligodeoxynucleotide synergistically inhibits tumor growth in vivo. J Korean Med Sci. 2011;26(10):1270-1276.
79. Yang RK, Kalogriopoulos NA, Rakhmilevich AL, et al. Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention. J Immunol. 2012;189(5):2656-2664.
80. Akeda T, Yamanaka K, Kitagawa H, et al. Intratumoral injection of OK-432 suppresses metastatic squamous cell carcinoma lesion inducing interferon- γ and tumor necrosis factor-α. Clin Exp Dermatol. 2012;37(2):193-194.
81. Betting DJ, Hurvitz SA, Steward KK, et al. Combination of cyclo-phosphamide, rituximab, and intratumoral CpG oligodeoxynucleotide successfully eradicates established B cell lymphoma. J Immunother. 2012;35(7):534-543.
82. Zhong H, Han B, Tourkova IL, et al. Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth. Clin Cancer Res. 2007;13(18 Pt 1): 5455-5462.
83. Son CH, Shin DY, Kim SD, et al. Improvement of antitumor effect of intratumoral injection of immature dendritic cells into irradiated tumor by cyclophosphamide in mouse colon cancer model. J Immunother. 2012;35(8):607-614.
84. Galili U. Conversion of tumors into autologous vaccines by intratumoral injection of alpha-Gal glycolipids that induce anti-Gal/alpha-Gal epitope interaction. Clin Dev Immunol. 2011;2011:134020.
85. Hamalukic M, Huelsenbeck J, Schad A, Wirtz S, Kaina B, Fritz G. Rac1-regulated endothelial radiation response stimulates extravasation and metastasis that can be blocked by HMG-CoA reductase inhibitors. PLoS One. 2011;6(10):e26413.
86. Raut CP, Boucher Y, Duda DG, et al. Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948). PLoS One. 2012;7(2):e26331.
87. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature. 2005;438(7070):946-953.
88. Fan Y, Du W, He B, et al. The reduction of tumor interstitial fuid pressure by liposomal imatinib and its effect on combination therapy with liposomal doxorubicin. Biomaterials. 2013;34(9):2277-2288.
89. Shayan R, Achen MG, Stacker SA. Lymphatic vessels in cancer metastasis: bridging the gaps. Carcinogenesis. 2006;27(9):1729-1738.
90. Oliver G, Harvey N. A stepwise model of the development of lymphatic vasculature. Ann N Y Acad Sci. 2002;979:159-165; discussion 188-196.
91. Lardinois D, Brack T, Gaspert A, et al. Bronchoscopic radioisotope injection for sentinel lymph-node mapping in potentially resectable non-small-cell lung cancer. Eur J Cardiothorac Surg. 2003;23(5): 824-827.
92. Chen X, Wang X, Wang Y, et al. Improved tumor-targeting drug delivery and therapeutic effcacy by cationic liposome modifed with truncated bFGF peptide. J Control Release. 2010;145(1):17-25.